Ingredients and solutions for the food industry
Microorganisms and active ingredients for human health
Lactic acid bacteria for the agri-veterinary sector

Sacco acquires the majority of Synbiotec Laboratori, a spin-off of UNICAM – University of Camerino

13/12/2021

Sacco, one of the leading and most historically relevant biotech companies in both research and the production of lactic bacteria and probiotics for the food, nutraceutical and pharmaceutical industries, has recently acquired the majority of Synbiotec, a spin-off company of the University of Camerino specialized in the research and development of probiotics for applications in human and animal nutrition.

The potential synergies between these two companies are numerous: both share the strategic goal of contributing to the improvement of both humans’ and animals’ welfare through the study, research and development of natural ingredients and processes; and both commit to supplying probiotic bacterial strains with the highest levels of quality and innovation always keeping in tune with the demands of a constantly evolving market.

“We are deeply convinced that the synergies existing between the two companies, which have over time had the chance to get to know each other, and which are further reinforced through this acquisition, will lead to the landmark establishment of a pole of excellence in the Italian industry of probiotics for human and animal health. This will also undoubtedly favour research, development and innovation in the production and improvement of products for the well-being of consumers. Another shared fundamental pillar for both companies, which paves the ground for virtuous cooperation, is the cardinal importance both assign to human capital for the achievement of their core goals.” says Martino Verga, CEO of Sacco Srl.

“We are thrilled to be able to share our probiotic research experience with a large international group like Sacco. The strength of its history and its global presence will allow us to explore together new applications for the probiotic market with the shared intention of improving the health and well-being of consumers. The participation of the Sacco group in Synbiotec is a great opportunity for our company, and I am sure it will help us grow and further establish ourselves in the market”, says Maria Cristina Verdenelli, President and Founding Partner of Synbiotec.

Latest News

19 March 2026
A regulatory achievement for Sacco System: our Heat-Inactivated CRL1505® receives GRAS status

An important regulatory goal has been achieved with the conclusion reached by an independent expert panel for the self-affirmed GRAS (Generally Recognized as Safe) determination of our postbiotic CRL1505® HI.

24 January 2026
SYNBIO®: Sacco System’s probiotic support for healthy ageing

The global population is ageing faster than ever before. In 2019, life expectancy at birth reached 72.8 years almost 9 years more than in 1990. In this context, staying healthy

22 December 2025
Sacco System grows in Latin America: BioInsumos in Uruguay and Sacco Brasil acquired.

The Group is accelerating its South American growth strategy through a twofold transaction: the acquisition of a Uruguayan company and the full absorption of its Brazilian subsidiary. The Group is

11 December 2025
Sacco System Presents PerforMilk®: Unlocking Milk’s Full Potential by Preserving Protein Quality 

Milk is the most precious resource in dairy production. High-quality dairy products start with high-quality milk—and in today’s rapidly evolving dairy landscape, protecting that quality has never been more critical. 

20 November 2025
Unveiling the survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model

“Survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model” is the title of the study that has been

07 February 2025
L. rhamnosus CA15 Achieves GRAS Status: A Milestone for Women’s Health

GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a

08 January 2025
Sacco System Australia’s Heat-Inactivated Postbiotics Receive Positive Recommendations from FSANZ

Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1

25 November 2024
News
Our 2023 sustainability report is online!

We are proud to present the fifth edition of our Sustainability Report, an opportunity to reflect on the milestones achieved and the challenges ahead…

16 April 2024
News
Sacco System is pleased to announce the grand opening of its development site in Australia.

Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland…

26 March 2024
News
Sacco System companies have been awarded as Sustainability champions by Ecovadis

At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici…

18 March 2024
News
List Biotherapeutics and Sacco System Announce Lead Share Agreement

List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement…

26 February 2024
News
CSL FRANCE becomes SACCO SYSTEM FRANCE

Sacco System is the international biotechnological company dedicated to the food, nutraceutical, and pharmaceutical industries…